Beijing Biostar Technologies, a Chinese developer of anti-tumour, small-molecule chemical drugs, announced on Thursday the completion of a Series E round at 890 million yuan (about $135 million).
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
